Pulmonary arterial hypertension (PAH) affected an estimated 192,000 individuals globally in 2021, disproportionately affecting women and older adults.

In patients with familial PAH, SMAD5 appears to be a novel gene that warrants consideration for genetic testing, according to ...

People with pulmonary arterial hypertension (PAH) experience a high disease burden and their quality of life worsens as their ...

The top articles about pulmonary arterial hypertension (PAH) in 2024 included FDA approvals, the effect of salt substitutes ...

Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

After the FDA approved both combination macitentan/tadalafil (Opsynvi) and the biologic therapy sotatercept (Winrevair) for ...

UK's Medicines and Healthcare products Regulatory Agency said on Tuesday it had approved Merck's therapy to treat a rare lung ...

The following is a summary of “Relevance of patient-centered actigraphy measures in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a qualitative interview study,” ...

By analyzing data on heart rate, activity, and sleep, these devices could help doctors monitor disease severity and reduce ...

Increasing average concentrations of sotatercept improved 6-minute walk distance, pulmonary vascular resistance, and levels of NT-proBNP.